IRadimed

IRadimed is a publicly traded medical device company with a singular focus on enhancing patient safety and continuity of care during MRI procedures. Founded on a legacy of innovation dating to the first FDA-cleared MRI monitor in 1987, the company has established a dominant position with its proprietary non-magnetic technology for patient monitoring and IV infusion. Its strategy leverages deep domain expertise, a robust intellectual property portfolio, and a razor-sharp focus on the high-growth MRI safety niche to drive consistent revenue growth and profitability. Recent financial performance demonstrates strong execution, with record results and a shareholder-friendly capital allocation policy including regular and special dividends.

Proprietary engineering platform for designing intrinsically non-magnetic and MRI-immune electronic and fluid delivery systems, enabling safe operation within high-strength static magnetic fields, RF pulses, and switching gradients.

IRadimed holds a near-monopoly in MRI-safe infusion pumps and a differentiated leadership position in portable MRI monitors against larger, less-specialized medtech firms. Competition in ferrous metal detectors is more direct, but IRadimed's 'Tru sense' technology addresses key customer pain points like false alarms.